Next Article in Journal
Targeting Smoothened as a New Frontier in the Functional Recovery of Central Nervous System Demyelinating Pathologies
Previous Article in Journal
Microduplication of 15q13.3 and Microdeletion of 18q21.32 in a Patient with Moyamoya Syndrome
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 19
Issue 11
10.3390/ijms19113676
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Int. J. Mol. Sci. 2017, 18(2), 401.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401

by
Anna M. Serwotka-Suszczak
1,
Alicja M. Sochaj-Gregorczyk
1,
Jerzy Pieczykolan
2,†,
Daniel Krowarsch
3,
Filip Jelen
4 and
Jacek Otlewski
1,*
1
Department of Protein Engineering, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland
2
Drug Discovery Department, Adamed Group, 05-152 Czosnow, Poland
3
Department of Protein Biotechnology, Faculty of Biotechnology, University of Wroclaw, 50-137 Wroclaw, Poland
4
Research and Development Department, Pure Biologics Ltd., 54-427 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
†
Current address: Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland.
Int. J. Mol. Sci. 2018, 19(11), 3676; https://doi.org/10.3390/ijms19113676
Submission received: 8 November 2018 / Accepted: 10 November 2018 / Published: 20 November 2018
Versions Notes
It has been brought to our attention that the affiliation of Dr. Jerzy Pieczykolan at the time when he was responsible for the work described in the paper [1] was not mentioned in the previous published version.
We would like to change the Dr. Jerzy Pieczykolan’ affiliation on Page 1 of paper [1] from:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; [email protected].
to the correct version, as follows:
Drug Discovery Department, Adamed Group, Czosnow 05-152, Poland; [email protected].
And add the following affiliation as the current address of Dr. Jerzy Pieczykolan:
Preclinical Development Department, R&D Celon Pharma Inc., 05-092 Lomianki/Kielpin, Poland; [email protected].
This correction does not cause any changes to results and conclusions in the original published paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Serwotka-Suszczak, A.M.; Sochaj-Gregorczyk, A.M.; Pieczykolan, J.; Krowarsch, D.; Jelen, F.; Otlewski, J. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401. [Google Scholar] [CrossRef] [PubMed]

Share and Cite

MDPI and ACS Style

Serwotka-Suszczak, A.M.; Sochaj-Gregorczyk, A.M.; Pieczykolan, J.; Krowarsch, D.; Jelen, F.; Otlewski, J. Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401. Int. J. Mol. Sci. 2018, 19, 3676. https://doi.org/10.3390/ijms19113676

AMA Style

Serwotka-Suszczak AM, Sochaj-Gregorczyk AM, Pieczykolan J, Krowarsch D, Jelen F, Otlewski J. Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401. International Journal of Molecular Sciences. 2018; 19(11):3676. https://doi.org/10.3390/ijms19113676

Chicago/Turabian Style

Serwotka-Suszczak, Anna M., Alicja M. Sochaj-Gregorczyk, Jerzy Pieczykolan, Daniel Krowarsch, Filip Jelen, and Jacek Otlewski. 2018. "Correction: Serwotka-Suszczak, A. M. et al. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells. Int. J. Mol. Sci. 2017, 18, 401" International Journal of Molecular Sciences 19, no. 11: 3676. https://doi.org/10.3390/ijms19113676

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop